Heska (NASDAQ:HSKA – Get Rating) was downgraded by equities researchers at Morgan Stanley from an “equal weight” rating to an “underweight” rating in a research report issued on Friday, The Fly reports.
A number of other research firms also recently issued reports on HSKA. Piper Sandler cut their price target on Heska from $170.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, November 14th. JPMorgan Chase & Co. cut their price target on Heska from $175.00 to $150.00 and set an “overweight” rating for the company in a research note on Monday, October 17th. StockNews.com began coverage on Heska in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Alliance Global Partners cut their price target on Heska from $155.00 to $119.00 and set a “buy” rating for the company in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Heska currently has an average rating of “Hold” and a consensus target price of $142.25.
Heska Price Performance
NASDAQ HSKA opened at $62.54 on Friday. Heska has a one year low of $58.00 and a one year high of $164.57. The stock has a 50-day moving average of $65.12 and a 200 day moving average of $78.38. The company has a market capitalization of $677.31 million, a price-to-earnings ratio of -39.83 and a beta of 1.40. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.61 and a current ratio of 7.18.
Heska (NASDAQ:HSKA – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The medical research company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.09 by $0.15. Heska had a positive return on equity of 0.09% and a negative net margin of 6.26%. The company had revenue of $61.49 million during the quarter, compared to the consensus estimate of $69.72 million. On average, sell-side analysts forecast that Heska will post 0.27 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Kevin S. Wilson purchased 3,440 shares of the company’s stock in a transaction on Thursday, December 22nd. The stock was acquired at an average cost of $59.64 per share, for a total transaction of $205,161.60. Following the completion of the transaction, the chief executive officer now directly owns 156,054 shares in the company, valued at approximately $9,307,060.56. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 11.00% of the company’s stock.
Hedge Funds Weigh In On Heska
Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of Heska by 0.8% during the first quarter. Bank of New York Mellon Corp now owns 102,736 shares of the medical research company’s stock worth $14,207,000 after acquiring an additional 828 shares during the last quarter. US Bancorp DE boosted its position in shares of Heska by 43.3% during the first quarter. US Bancorp DE now owns 4,720 shares of the medical research company’s stock worth $653,000 after acquiring an additional 1,426 shares during the last quarter. Citigroup Inc. boosted its position in shares of Heska by 12.1% during the first quarter. Citigroup Inc. now owns 11,128 shares of the medical research company’s stock worth $1,539,000 after acquiring an additional 1,205 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Heska by 58.5% during the first quarter. MetLife Investment Management LLC now owns 5,506 shares of the medical research company’s stock worth $761,000 after acquiring an additional 2,032 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Heska by 8.7% during the first quarter. Rhumbline Advisers now owns 25,409 shares of the medical research company’s stock worth $3,514,000 after acquiring an additional 2,023 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors.
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Heska, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Heska wasn’t on the list.
While Heska currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.